pan-Canadian Pharmaceutical Alliance (pCPA): August 2020 Trends and Insights August 2020 Highlights: 2 products completed CADTH review 2 products initiated pCPA negotiations 1 negotiation was completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Files Under pCPA Consideration: CADTH issued 2 new recommendations in August (25 files as of August 31). PRODUCT INDICATION SPONSOR … Read More →
MORSE Consulting Bolsters Private Payer Expertise
Toronto, September 9, 2020 – MORSE Consulting is pleased to announce that Sal Cimino has joined our team as Senior Consultant, Private Drug Plans. The private payer market is playing an increasingly important role in ensuring a product’s reimbursement success in Canada. With the introduction of new specialty biologics and gene therapies, private payers are turning to new cost containment strategies that strongly resemble … Read More →
Impact of COVID19 on pCPA Negotiations Starting to Emerge
pan-Canadian Pharmaceutical Alliance (pCPA): July 2020 Trends and Insights July 2020 Highlights: 6 products completed CADTH review 6 products initiated pCPA negotiations 7 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Trends are beginning to emerge regarding impact of COVID19 on pCPA negotiations with 3 months of experience to consider. In general, … Read More →
Some Positive Indicators as Number of Files Under Consideration Remains Flat – June 2020
pan-Canadian Pharmaceutical Alliance (pCPA): June 2020 Trends and Insights June Highlights: 4 products completed CADTH review 7 products initiated pCPA negotiations 4 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Files Under pCPA Consideration: CADTH issued 4 new recommendations in June (23 files as of June 30). PRODUCT INDICATION SPONSOR HTA … Read More →
CADTH Pharmaceutical Reviews Update, Issue 16
Consultations on Enhanced and Aligned Review Processes and Program Updates. CADTH released its Pharmaceutical Reviews Update — Issue 16 on June 25, 2020. It includes two consultations with respect to enhanced and aligned review processes, in addition to program update announcements. Highlights of the consultations and program updates are described below. Topic MORSE Note Consultations – Feedback due to CADTH by August … Read More →
No Files Completed or Closed by the pCPA – May 2020
pan-Canadian Pharmaceutical Alliance (pCPA): May 2020 Trends and Insights May Highlights: 8 products completed CADTH review 5 products initiated pCPA negotiations 0 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation There was an evident slow down in May as the pCPA continues to adjust to the evolving COVID-19 situation. No negotiations were … Read More →
Early Insights into pCPA Prioritization
pan-Canadian Pharmaceutical Alliance (pCPA): April 2020 Trends and Insights April Highlights: 6 products completed CADTH review 4 products initiated pCPA negotiations 11 negotiations were completed with an LOI 2 negotiations were closed without an LOI 2 files were closed without negotiation In keeping with pCPA’s communication to industry associations, early trends into their management of files during the challenges associated with COVID indicate … Read More →
CADTH Business Plan 2020-2021 Insights
CADTH recently released their annual business plan for 2020-2021. In this, the last year of their three-year strategic plan, CADTH aims to deliver on a number of priority initiatives, several of which may have implications for industry, as described below. 1) Operationalize the Life Cycle Approach to Health Technology Assessment (HTA) Under this priority initiative, CADTH signals their continued commitment to the life … Read More →
Summary of CADTH Pharmaceutical Reviews Update – Issue 15
CADTH released its Pharmaceutical Reviews Update — Issue 15 on April 29, 2020. Please find below MORSE Consulting’s summary of this update. Topic MORSE Note 1. COVID-19 Update CADTH will continue to deliver on core activities, including the completion of ongoing drug reviews and initiation of new reviews in accordance with target timelines, and progress reports will continue to be posted on the CADTH … Read More →
April 2020 Update to The Canadian Reimbursement Trends & Timelines Report – Now Available
Toronto, April 27, 2020 – MORSE Consulting is pleased to release our April 2020 Update to the Canadian Reimbursement Trends and Timelines report – a comprehensive, credible and relevant source of market access intelligence. This 50+ PowerPoint report is aimed at assisting market access professionals plan for future launches and also serves as a valuable education tool for both internal and external stakeholders. What’s … Read More →
New pCPA Website & Available Data
pan-Canadian Pharmaceutical Alliance (pCPA): March 2020 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has launched a new website (https://www.pcpacanada.ca) with searchable data regarding brand name drug negotiations status and highlighting pCPA activity in the last four weeks. Highlights of the pCPA activity in March are: 5 products completed CADTH review, for a total of 16 files under consideration; 2 products initiated pCPA … Read More →
pCPA – The Beginning of a Period of Uncertainty?
pan-Canadian Pharmaceutical Alliance (pCPA): February 2020 Trends and Insights Due to the COVID-19 outbreak, the pCPA is implementing measures to work within the current reality while still attempting to meet its mandate. Consequently, some existing negotiations may be delayed or temporarily halted while the negotiating jurisdiction focuses on responding to the COVID-19 situation. The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the February 29, … Read More →
MORSE Consulting Strengthens HTA Strategy and Payer Expertise
Toronto, February 18, 2020 – MORSE Consulting is pleased to expand and strengthen our service offering with the addition of Anita Carrie and Roy Cairns. Affordability of effective and innovative medications within the current Canadian public funding model is becoming very challenging for the healthcare system. Increasing budgetary constraints coupled with complex treatments requiring consideration of different sources and levels of evidence are an … Read More →
pCPA Closing in on 300 Completed Negotiations
pan-Canadian Pharmaceutical Alliance (pCPA): January 2020 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the January 31, 2020 status of brand negotiations. Highlights since the last update include: ● 2 products completed CADTH review, for a total of 9 files under consideration; ● 4 products initiated pCPA negotiations, for a total of 34 active negotiations; ● 2 negotiations completed for a … Read More →
MORSE Consulting Releases its Third Annual pCPA Year in Review Infographic (2019 Edition)
MORSE Consulting is pleased to release our Third Annual pCPA Year in Review infographic – 2019 Edition. This resource is aimed at helping market access stakeholders understand the top-line pCPA highlights from 2019. This infographic compares year-over-year metrics including: pCPA activity summary; average time to complete a negotiation; files adjudicated by the pCPA; and average negotiation duration by source. This infographic is an excerpt from the 2019 update … Read More →
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2020 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
MORSE Market Access Signals - Latest in Pharmaceutical Reimbursement
